SCHEMBL377306

SCHEMBL377306

C=C1C=C[C@H]([C@@H](C)CC(=O)C=C(C)C)CC1

nearest known ligand 0.45

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.45
STAT3 P40763 1/20 0.38
ACLY P53396 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29756085 1.00 PTPN1 (0.45) PTPN1STAT3ACLY
SCHEMBL377474 1.00 PTPN1 (0.45) PTPN1STAT3ACLY
SCHEMBL21757939 0.78 PTPN1 (0.40) PTPN1STAT3
SCHEMBL30455949 0.78 PTPN1 (0.40) PTPN1STAT3
SCHEMBL158316 0.75 NR1I2 (0.37) PTPN1
SCHEMBL29349988 0.75 NR1I2 (0.37) PTPN1
SCHEMBL29456643 0.75 NR1I2 (0.37) PTPN1
SCHEMBL13767028 0.74 STAT3 (0.38) PTPN1STAT3
SCHEMBL19117757 0.74 STAT3 (0.41) PTPN1STAT3
SCHEMBL3092052 0.74 STAT3 (0.41) PTPN1STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050393-A1 COMPOSITIONS AND USES THEREOF FOR TREATING OR PREVENTING VIRAL INFECTIONS GILVERDI - HEALTH AND BEAUTY LTD (IL) 2024-02-15 US claimed
WO-2022137241-A1 COMPOSITIONS AND USES THEREOF FOR TREATING OR PREVENTING VIRAL INFECTIONS GILVERDI - HEALTH AND BEAUTY LTD (IL) 2022-06-30 WO claimed
WO-2020081357-A1 BEVERAGE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME Golden Spice Liquors LLC (US) 2020-04-23 WO claimed
US-20200115663-A1 BEVERAGE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME Golden Spice Liquors LLC 2020-04-16 US claimed
US-20100093870-A1 HERBAL MEDICAMENTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2010-04-15 US claimed
CN-100528149-C A composition for treating neurocerebrovascular disorders COUNCIL SCIENT IND RES (IN) 2009-08-19 CN claimed
EP-1453528-B1 COMPOSITIONS CONTAINING CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS COUNCIL SCIENT IND RES (IN) 2009-07-22 EP claimed
US-20080312333-A1 Agent for Preventing/Ameliorating Life Style-Related Diseases Containing Turmeric Essential Oil Component KANEKA CORPORATION (JP) 2008-12-18 US claimed
EP-1752144-A1 AGENT FOR PREVENTING/AMELIORATIG LIFE STYLE-RELAETD DISEASES CONTAINING TURMERIC ESSENTIAL OIL COMPONENT Kaneka Corporation (JP) 2007-02-14 EP claimed
US-20060051438-A1 Herbal medicaments for the treatment of neurocerebrovascular disorders COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2006-03-09 US claimed
US-6991814-B2 Herbal medicaments for the treatment of neurocerebrovascular disorders COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-01-31 US claimed
CN-1615144-A A composition for treating neurocerebrovascular disorders COUNCIL SCIENT IND RES (IN) 2005-05-11 CN claimed
EP-1453528-A2 COMPOSITIONS CONTAINING CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS Council of Scientific and Industrial Research (IN) 2004-09-08 EP claimed
US-20040033277-A1 Herbal medicaments for the treatment of neurocerebrovascular disorders COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2004-02-19 US claimed
WO-2003051380-A2 COMPOSITIONS CONTAINEING CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2003-06-26 WO claimed
EP-4376973-B1 MOLECULARLY IMPRINTED POLYMER, AND ITS USE IN THE QUANTIFICATION OF A PESTICIDE IN A SAMPLE ECOLE SUPERIEURE PHYSIQUE & CHIMIE IND VILLE DE PARIS (FR) 2025-07-02 EP disclosed
WO-2025133916-A1 TURMERIC OIL ESSENTIAL-OIL BISABOLENE SESQUITERPENOIDS IN THE TREATMENT OF NON-NEURODEGENERATIVE DISEASES UNIVERSIDAD DE CUENCA (EC) 2025-06-26 WO disclosed
US-20040033277-A1 Herbal medicaments for the treatment of neurocerebrovascular disorders COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2004-02-19 US disclosed
WO-2003051380-A2 COMPOSITIONS CONTAINEING CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2003-06-26 WO disclosed
WO-2003051380-A2 COMPOSITIONS CONTAINEING CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060051438-A1 Herbal medicaments for the treatment of neurocerebrovascular disorders NR0B1, NR0B2, CYP46A1 PTPN1 4865/4885STAT3 1658/4885ACLY 3292/4885
US-20100093870-A1 HERBAL MEDICAMENTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS NR0B1, NR0B2, CYP46A1 PTPN1 4865/4885STAT3 1658/4885ACLY 3292/4885
US-20040033277-A1 Herbal medicaments for the treatment of neurocerebrovascular disorders NR0B1, NR0B2, CYP46A1 PTPN1 4865/4885STAT3 1658/4885ACLY 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.